For instance, blocking the inhibitory receptor NKG2A unleashes both NK cells and T cells, and the anti-NKG2A antibody Monalizumab promoted anti-tumour responses in a recent clinical trial[116]. The gene discussed is KLRC1; the disease is neoplasm.